Aptamer Group Plc (LSE:APTA) has spent most of its listed life valued as a sub-scale contract research Business with a perpetual funding question hanging over it. That picture is starting to shift. The York-based developer of Optimer synthetic antibody alternatives reported on 13 July 2026 that Revenue for the year to 30 June 2026 rose roughly 25% to around £1.5m, that its sales pipeline had swelled 55% to £4.8m since January, and that its first licensing income had begun to flow.

The question is whether a still loss-making business can convert that momentum into the higher-margin Royalty streams management has promised before the cash raised in April 2026 runs down. With in vivo radiopharmaceutical data due by the end of 2026 and a new joint broker appointed, the next six months look unusually eventful for a company valued at under £20m.

Trading update: revenue up 25% and pipeline up 55%

On 13 July 2026 Aptamer issued an unaudited trading update for the year ended 30 June 2026. Revenue is expected to be approximately £1.5m, up around 25% from £1.2m in FY2025, driven by fee-for-service programmes and, for the first time, licensing revenues from the December 2025 agreements with Twist Bioscience and Alphazyme covering enzyme-modulating Optimers.

The pipeline figures were arguably more important than the headline revenue. The company put its sales pipeline at £4.8m, a 55% increase on the £3.1m disclosed in January 2026, and said it had already booked £0.6m of orders for FY2027. Net proceeds of £4.1m from the April 2026 fundraise gave a cash runway "into at least 2028".

Chief executive Dr Arron Tolley said: "We report strong revenue growth for FY2026, reflecting commercial momentum and successful delivery across the business." He pointed to collaborations with top-tier pharmaceutical companies progressing through Optimer selection and to the radiopharmaceutical programme with a top-three global pharma company. On 20 August 2026 the company appointed Cavendish Capital Markets as joint corporate broker alongside Turner Pope Investments to broaden research coverage and institutional engagement.

What Aptamer does

Founded in 2008 and admitted to AIM in December 2021, Aptamer Group develops Optimer binders: short synthetic oligonucleotide molecules designed to bind a target with the precision of an antibody but with greater stability and lower Manufacturing cost. The company positions itself in what it describes as a $210bn antibody alternatives market.

Revenue comes from two sources. The larger is fee-for-service discovery, in which pharmaceutical, diagnostics and consumer goods customers pay Aptamer to develop Optimers against their chosen targets; repeat customers include several top-20 pharmaceutical groups and Unilever, which has commissioned two deodorant-related programmes. The newer source is licensing: Aptamer raised its stock of licensable Optimer Assets from four to 11 during FY2025 and has out-licensed enzyme-modulating binders to Twist Bioscience and Alphazyme for royalties on net sales.

The company is also building a proprietary pipeline: Optimer-based delivery vehicles for oligonucleotide therapeutics targeting the kidney, fibrotic tissue and the blood-brain barrier, a radioligand therapy programme, and an AI discovery model trained on 450,000 sequences across 42 protein targets. Diagnostics work, including a Bundibugyo Ebola test programme launched on 8 July 2026, rounds out the portfolio.

Financial performance: narrowing losses on a small base

The latest audited figures are for the year ended 30 June 2025, published on 14 October 2025. Revenue rose 40% to £1.20m from £0.86m, and Gross Profit more than doubled to £579,000, lifting gross Margin to 48% from 29%. Administrative expenses fell to £2.9m from £3.2m as headcount was cut from 38 to 31. Adjusted EBITDA loss narrowed to £2.2m from £2.8m, operating loss to £2.54m from £3.08m, and loss before tax to £2.57m from £3.14m. Basic loss per share was 0.14p (FY2024: 0.71p). Cash at 30 June 2025 was just £1.1m, and the directors flagged a material uncertainty over going concern, echoed in the auditor's otherwise unqualified opinion.

Interim results for the six months to 31 December 2025, published on 25 March 2026, showed revenue up 27% to £0.83m (H1 FY2025: £0.65m) with gross margin improving to 56%. Adjusted EBITDA loss was £1.0m (£1.1m), operating loss £1.24m (£1.18m) and loss before tax £1.24m (£1.20m). Loss per share was 0.04p. Period-end cash was £1.5m, helped by a £2.0m gross placing in July 2025.

Between 25 March and 13 April 2026 the company then raised approximately £4.5m gross through a placing, subscription and retail offer at 0.6p per share, with all directors participating; net proceeds were £4.1m and roughly 758m new shares took the total in issue to around 3.4bn. At the time of writing, the shares trade at about 0.525p, below the issue price, for a Market Capitalisation of around £18m. No Dividend is paid.

What could drive the stock next?

The most clearly signposted catalyst is in vivo animal data from the targeted radiopharmaceutical programme, targeted by the end of 2026. Optimer material has been shipped to partners, radiolabelling has been achieved at greater than 99% radiochemical purity, and the company says the data is intended to support partnering discussions.

Full-year results for FY2026, likely in October on last year's timetable, will confirm the £1.5m revenue figure and the post-fundraise cash position. Investors will also watch for conversion of the £4.8m pipeline into contracts, further licensing deals from the 11-asset portfolio, royalty receipts from Twist's library preparation kit launched in February 2026, and progress on AI-generated Optimer candidates now in laboratory testing. The Ebola and fortified-foods programmes are early-stage but could generate newsflow.

Risks investors should watch

Aptamer remains loss-making, with an FY2025 operating loss of £2.54m against FY2026 revenue of around £1.5m. The April 2026 raise extended the runway only "into at least 2028", so unless revenue and licensing income accelerate materially, a further Equity raise, and further dilution, is a realistic prospect. The current share price already sits below the 0.6p placing level.

Revenue is lumpy and concentrated: single pharma partners have accounted for contracts worth £769,000 and £360,000, so one delayed programme moves the numbers. Licensing income depends on partners' commercial success. The therapeutic pipeline is preclinical, and unfavourable in vivo results would remove a key plank of the Investment case. The company competes with far better-capitalised antibody and aptamer businesses, and with a sub-1p share price, Liquidity and Volatility are significant considerations. The FY2025 going-concern warning is a reminder of how thin the margin for error has been.

Outlook

Aptamer Group enters FY2027 with more cash, a larger pipeline, its first licensing revenues and a healthcare-specialist broker behind it. The audited FY2026 results and year-end radiopharmaceutical data will show whether July's commercial momentum is durable and whether the proprietary pipeline can attract a partner. Pipeline conversion, cash burn against the stated runway and the timing of any next funding requirement are the metrics to monitor. The story has improved; the execution risk has not gone away.